EUCTR2007-002243-25-FRActive, not recruitingNot Applicable
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- ovartis Pharma Services AG
- Enrollment
- 675
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Female
Inclusion Criteria
- •All patients randomized in the CAAE581A2203 core study
- •Patients who have signed a written informed consent before any trial procedure is performed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Patients who have taken any anti-osteoporosis therapy since study participation (core or extension E1)
Investigators
Similar Trials
Active, not recruiting
Phase 1
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosisOsteoporosisEUCTR2007-002243-25-SKovartis Pharma Services AG675
Active, not recruiting
Not Applicable
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosisOsteoporosisEUCTR2007-002243-25-ATovartis Pharma Services AG675
Active, not recruiting
Not Applicable
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosisOsteoporosisEUCTR2007-002243-25-PLovartis Pharma Services AG675
Active, not recruiting
Not Applicable
An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosisOsteoporosisEUCTR2007-002243-25-CZovartis Pharma Services AG675
Recruiting
Phase 1
An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone DeficiencyIdiopathic Growth Hormone DeficiencyCTIS2023-504020-25-00umos Pharma Inc.69